Risk-benefit ratio must be taken into account
- 14 December 1996
- Vol. 313 (7071) , 1553
- https://doi.org/10.1136/bmj.313.7071.1553a
Abstract
EDITOR,—P J Barrett and colleagues report that mefloquine is associated with an excess of neuropsychiatric adverse events compared with chloroquine plus proguanil (27.4% v 16.0%).1 While there are similarities in methodology between the authors' study and Steffen et al's larger study,2 there are crucial differences in assessment criteria. I propose that any differences in incidence reports are a function of the defining criteria and that this may account for the disparities in perceptions of the tolerability of mefloquine. Nevertheless, I wish to make …Keywords
This publication has 4 references indexed in Scilit:
- Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellersBMJ, 1996
- Neuropsychiatric reactions with mefloquine chemoprophylaxisThe Lancet, 1996
- Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East AfricaThe Lancet, 1993
- Long-term malaria prophylaxis with weekly mefloquineThe Lancet, 1993